Hypercoagulation and the risk of thromboembolic events is also a common feature of CS and COVID-19 (113, 114) (Table 2) and implies several mechanisms such as increased levels of factor VIII, fibrinogen, and von Willebrand factor (vWF); shorter activated partial thromboplastin time (92, 93); reduction in fibrinolysis, or elevated antiphospholipid antibodies (94, 95). This evidence concerns the gene VWF and Cowden syndrome 1.